Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

infection * infection 97

SKeyword

Abstract

SKeyword

Abstract

ent in persons with HIV
ocyte depletion in HIV-1
ssion to disease in SIV
nd CD8 T-cells in HIV-1
us load in pediatric HIV
CD4+ T cells during HIV
nsil during primary HIV
e of glycosylation in HIV
nt enhancement of HIV
from subsequent HIV-1
Saliva neutralizes HIV-1
is mainly at the level of
vity/The effect of HIV-1
-1 infected cells/HIV-1
d susceptibility to HIV-1
eath in primary acute
interactions during HIV
s during primary HIV-1
ring the course of HIV-1
ulmonary tuberculosis
ith other subtype HIV-1
udy/Rhodococcus equi
onella species and HIV
utropenia and bacterial
Ilosis in the clinic of HIV
s for tuberculosis in HIV
bacterium tuberculosis
f Mycobacterium bovis
bacterium tuberculosis
India/Spectrum of HIV
ests in patients with HIV
redictive factor of a HIV
- High risk factor in HIV
associated with the HIV
cterium avium complex
tation of mycobacterial
rapy predictive of MAC
m intracellulare complex
among women with HIV
eropositivity at the HIV
controls/Syphilis in HIV
matic patients with HIV
volving hepatitis C virus: Risk factor analysis of
en with suspicion of HIV
s with symptomatic HIV
cies in children with HIV
n papilloma virus (HPV)
ervical cancer and HIV
uman papillomavirus
men: An assessment of
helial changes and HIV
96) in Liguria, Italy/HIV
The initial opportunistic
es for treatment of HIV
or the treatment of HIV
itiated at primary HIV-1
ts of the advanced HIV
3TC + indinavir for HIV
erleukin-2 in early HIV
munotherapy for HIV-1
n of Europeans with HIV
y/Palliative care for HIV
ng for children with HIV
ns with and without HIV
ciated with incident HIV
/Risk behaviors for HIV
Sex, needles, and HIV
nfection/Effect of HIV
alia/Risk factors for HIV
seases (STD) and HIV
actors/HIV-1 and HIV-2
idow inheritance in HIV
ences in the risk of HIV
tment and incident HIV

sers (IDUs) against HIV
n Quebec City/HIV-1
nd responding to HIV
elphia/lncidence of HIV
and of hepatitis A virus: Properties of the French SF-36/ 14359
/Limited CD4+ T-cell renewal as 270*/21103
/Perturbations in the CD4+ TCR 21104
until end stage disease/Increase 268*/21108
/Plasma L-selectin level correlat 21115
and treatment/No evidence for p 21121
/Evidence of histologic changes i 21128
/Role of glycosylation in HIV 332*/21131
correlates to viral load and predic 21132
/In vitro evidence of HIV-2 protec 21136
by displacing envelope gp120 fro 21143
as heat-killed organisms mediat 21145
on CD45 phosphatase activity/T 21151
induces alterations in cellular ge 21152
of peripheral blood mononuclear 21156
/Expression of molecules respon 21161
/Macrophages-mediated CD8+ 275*/21164. Relationship with HIV-1 RNA, T 21173
/Changes in serum interleukin-1 21187
/Regulation of macrophage infla 21189
in Thailand: One year interim rep 21197
in AIDS patients - GESEDA and 22111
/Invasive Salmonella species an 22112
in acquired immunodeficiency sy 22121
/Legionellosis in the clinic of HIV 22122:A meta-analysis of randomized 451*/22124
in HIV-1 infected patients with pr 22138
and risk of exposition among We 22143
in HIV infected patients, a radiolo 22148
in tuberculosis (TB) - Urban and 22152
/Diagnostic use of tuberculin test 22160
/The serosal tuberculous (STB) 22161
evolution upon a lot of children fr 22164
/Broncho-pulmonary tuberculosi 22165
in Madrid: Low incidence in a pro 22168
after initiating of highly active anti 22172?/ls a response to amikacin thera 22173
in HIV-infected children/Mycoba 22174
/Drug use and STD prevalence/i 22196
in a discordent couple: A study c 22200
compared to HIV-negative contr 22202
/Correlation between oropharyn 22214
in HIV co-infected patients treate 17*/22243
/Detection of GB virus-C/hepatiti 22250
/HBS antigen in children with sus 22274
/A phase I dose escalation study 22281
/Malignancies in children with HI 22300
in HIV-positive and HIV-negative 22303
in Abidjan, C6te d'lvoire/Case-c 622*/22305

haviours related to HIV
icago, 1997-1998/HIV
users/HIV-1 and HTLV
st risk/High rate of HIV
7/A cohort study of HIV
ease the spread of HIV
protection against HIV
ween placental malaria
cted at enrollment/HIV
ssion in utero/Placenta
rus in women with triple
venting perinatal HIV-1
en at high risk for HIV-1
ission of HIV-1 group O
e on maternal-child HIV
osures resulting in HIV
I exposure/Risk of HIV
ransmission of HIV/An
a/Risk factors for HIV-1
ehaviour and risk to HIV
ors associated with HIV
simplex type 2 (HSV-2)
rs of Haitian origin/HIV
-demography of genital
and C (HBV and HCV)
tis B and C and syphilis
associated risks of HIV
be associated with HIV
nd prevalence of HIV
elated to risk for HIV
les: A risk factor of HIV
erty on women's risk of
facilitating factor in HIV
a/Analysis of HIV/AIDS
al transmission of HIV-1
s/Determinants of HIV
87-1997/Trends in HIV
hilippines to HIV/AIDS
ce center in Rome/HIV
sco/Prevalence of HIV
workers in Guyana/HIV
avioural aspects of HIV
Brazil/Correlates of HIV
dicator of risk from HIV
n retroviral and syphilis
997/Prevalence of HIV
ce for increasing of HIV
behavior related to HIV
odeficiency virus (HIV)
ts/Epidemiology of HIV
g demographics of HIV
dren/The impact of HIV
about disclosure of HIV
y and duration of HIV 1 -ders in patients with HIV
tions of changes in HIV
e course of established
body response in HIV-1
ties with respect to the
HIV-1 envelope early in
term survivors of HIV-1
apy during primary HIV
ollowing HIV-1 clade-B
esponses in advanced
cape mutations in HIV-1
ated inhibition of HIV-1
T-cell expansions in HIV
c T cells/Effect of HIV-1
ndividuals resist in vitro
cell production in HIV-1
by CD8+ T cells in HIV
sion in paediatric HIV-1
mmunity in acute HIV-1
en in patients with HIV1
opians: Effects of HIV-1

mune activation in dual
mparative prevalence of
d risk factors for HHV-8
orn to mothers with HIV
erpesvirus 8 (HHV8)

among injecting drug users in Vi 23213
among younger drug injectors in 23226
in northeast Brazil: Differences f 23231
in homeless young injectors: Sex 23233
among IDUs and natural history 23244
between women/IDUS men's se 23249
also when inoculated parenterall 23255
and increased risk of mother-to-i 461*/23268
due to breastfeeding in a cohort 457*/23270
in HIV-1 transmission in utero/PI 23277
/Maternal-infant transmission of 23293
in newborns delivered within one 23305
from Sio Paulo, Brazil/No evide 23307
in Yaounde, Cameroon/Mother-t 23318
and its prevention among wome 23320
in health care workers - United S 23329
in health care workers after occu 23336
control program to decrease the 23340
in a rural population of 15,000 ad 23356
/Travel, sexual behaviour and ris 23358
in heterosexuals attending anon 23359
in a cohort of Zimbabwean men 23363
is associated with travel back to 23368
with Chlamydia trachomatis in C 23373
with HIV transmission from HIV p 23378
in a different risk behaviour grou 23379?/Could the REACH model be th 23384
among female, street-based sex 23407
among female partners of male f 23441
among bisexual men in a cohort f 23448
among young females/Drug abu 23465
in the USA/Gender, power and 23466
and spread/Early widowhood as 23470
risk in young women living in Bue 23504
among women in Honduras/Ris 23506
in a cohort of native Canadian inj 23513
rates among New York State (N 23516:An ethnography and interventio 23533
among transsexual sex workers f 570*/23534
in transgendered individuals in S 23536
and syphilis among female com 23538
amongst the sex workers of Agra 23549
among incarcerated women in Vi 23551
/AIDS in prisons- The history of I 23555
among Macanao's fishermen an 23561
in prison system of Rio de Janeir 23563
in a prisoners population, Seneg 23575
among women working in entert 23582
in sexually active Ghanaian wom 23593
among indigent patients/Epide 23595
at a university medical center ho 24114
on families with one/several infe 24165
diagnosis to their children/Paren 24175
in American women/Reduced fe 24198
/Psychiatric disorders in patients 24221
/Health care workers' perception 24357
with HIV-1 primary isolates in the 330*/31103
is directed against viral debris rat 331*/31104
of primary macrophages with aut 31105
and subsequent disease progres 31107
/HIV-1 specific immune respons 31114
is associated with rapid stabilizat 109*/31121
/Cross-clade envelope gp160, g 601*"/31122
/Prolonged suppression of HIV-1 112*"/31124
/Rare occurrence of CTL escape 31125
of macrophages: p38 MAPK is th 31126
/Phenotypic characterisation of T 31136
on chemokine receptor expressi 31141
with macrophage tropic HIV-1 BaL 31154
/Telomere length and telomeras 271*/31168
correlates with viral load and CD 116*"/31170
predicts disease progression/Alt 31176
following antiretroviral therapy/I 115*/31177
/Effects of triple antiretroviral the 31178

/Immunohaematological referen 31183
with HIV and Mycobacterium tub 31184
by human herpes virus type 8 in t 31189
among women participants of th 31190
/Human herpesvirus-8 seroprev 31191
of peripheral blood cells (PBMCs 31196

in HIV+ women/Relationship bet
rates and treatment outcomes/H
in women attending STD clinics i
and visceral leishmaniasis in a M
(01) among Singaporean AIDS p
/Access to combination antiretro
/OZCOMBO 1: A randomised, o
/Full compliance sustains viral su
/Effect of the new antiviral therap
in pretreated patients with less th: Preliminary results/A randomis
using DNA based vaccines/Imm
/Euthanasia: The opinion of Euro

22313
22315
22318
22325
22332
22333
22348
22384
22392
22403
22414
22418
46*/22426

in a skilled nursing facility/Palliat 505*/22427
/Nurse's experiences caring for c 22457
at the University Hospital Antwer 62*/22459
in San Francisco/Objective: To c 23101
among men who have sex with m 23103
among young injection drug usin 23104
on the natural history of anal hum 23114
in homosexual men in Sydney, A 23124
incidence among men who have 23140
in pregnant women in the Gambi 23164: Experience in rural Uganda/Wi 23167
among young adult recently initia 23168
among persistently injecting dru 23179?/Do A32 CCR-5 deletions prote 23180
among drug users attending a ne 23182
associated with injecting drug us 23188
among injection drug users in Ph 23192
during an intravenous opiate mai 23211